Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | DHODH | Q02127 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6114293 | 0.99 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTDHODHKDM4ENPSR1 | |
| SCHEMBL8738345 | 0.85 | CDK5 (0.53) | SMN1; SMN2MAPTKDM4ERAB9ANPC1 | |
| Bromide SCHEMBL6114093 | 0.84 | CDK5 (0.52) | SMN1; SMN2MAPTKDM4ERAB9ANPC1 | |
| SCHEMBL4924576 | 0.83 | NPC1 (0.59) | SMN1; SMN2MAPTDHODHKDM4ENPSR1 | |
| SCHEMBL8738730 | 0.83 | SMN1; SMN2 (0.74) | SMN1; SMN2MAPTDHODHKDM4ENPSR1 | |
| Hydrochloric Acid SCHEMBL6114152 | 0.82 | SMN1; SMN2 (0.72) | SMN1; SMN2MAPTDHODHKDM4ENPSR1 | |
| SCHEMBL2832890 | 0.78 | ALDH1A1 (0.48) | SMN1; SMN2MAPTDHODHKDM4ENPSR1 | |
| SCHEMBL8737987 | 0.78 | ALDH1A1 (0.71) | SMN1; SMN2MAPTKDM4ERAB9ANPC1 | |
| Bromide SCHEMBL6114146 | 0.77 | ALDH1A1 (0.73) | SMN1; SMN2MAPTKDM4ERAB9ANPC1 | |
| SCHEMBL1593094 | 0.76 | L3MBTL1 (0.54) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129842-A1 | BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION | MMP1, MMP9, MMP2 | SMN1; SMN2 4061/4885MAPT 3531/4885DHODH 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.